Go to deals
Healthcare

Pharmazon has received a minority investment from a private investor

The shareholders of Pharmazon have sold the company to a private investor.

Pharmazon is a B2B distributor of OTC and parapharmacy products to French pharmacies. Its core business is to buy products directly from laboratories, negotiating good conditions and selling them online through a modern website which looks similar to Amazon.com.

The company's shareholders are the CEO and General Director.

Oaklins' team in France advised the seller in this transaction.

Parties

Talk to the deal team

Ludovic Beaulieu

Senior Advisor
Paris, France
Oaklins France

Antoine Lemaire

Partner
Paris, France
Oaklins France

Related deals

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Healthcare

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval

Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.

Learn more
Rare Patient Voice has been acquired by Konovo
Healthcare | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Learn more
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more